Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Figure 2

Kinetics of appearance of irAEs according to organ system involved [11]; adapted with permission from Weber et al. 2012 [11].